An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX®. [electronic resource]
Producer: 20140508Description: 2561-9 p. digitalISSN:- 1433-2965
- Aged
- Aged, 80 and over
- Algorithms
- Bone Density -- drug effects
- Bone Density Conservation Agents -- administration & dosage
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Humans
- Indoles -- administration & dosage
- Kaplan-Meier Estimate
- Lumbar Vertebrae -- physiopathology
- Middle Aged
- Osteoporosis, Postmenopausal -- drug therapy
- Osteoporotic Fractures -- physiopathology
- Raloxifene Hydrochloride -- therapeutic use
- Risk Assessment -- methods
- Spinal Fractures -- physiopathology
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.